Urology
Volume 75, Issue 2 , Pages 447-453 , February 2010

Urinary Prostate Cancer 3 Test: Toward the Age of Reason?

  • Virginie Vlaeminck-Guillem

      Affiliations

    • Department of Molecular Oncology and Transfert, Lyon Sud Hospital, Pierre-Bénite, France
    • Medical Faculty Grange Blanche, Lyon 1 University, Lyon, France
    • Corresponding Author InformationReprint requests: Virginie Vlaeminck-Guillem, M.D., Ph.D., Unité Médicale d'Oncologie Moléculaire et Transfert, Centre de Biologie Sud, Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre-Bénite Cedex, France
    • ,
  • Alain Ruffion

      Affiliations

    • Medical Faculty Grange Blanche, Lyon 1 University, Lyon, France
    • Department of Urology, Lyon Sud Hospital, Pierre-Bénite, France
    • Medical Faculty Lyon Sud, Lyon 1 University, Lyon, France
    • ,
  • Jean André

      Affiliations

    • Department of Molecular Oncology and Transfert, Lyon Sud Hospital, Pierre-Bénite, France
    • Medical Faculty Lyon Nord, Lyon 1 University, Lyon, France
    • ,
  • Marian Devonec

      Affiliations

    • Department of Urology, Lyon Sud Hospital, Pierre-Bénite, France
    • Medical Faculty Lyon Sud, Lyon 1 University, Lyon, France
    • ,
  • Philippe Paparel

      Affiliations

    • Department of Urology, Lyon Sud Hospital, Pierre-Bénite, France
    • Medical Faculty Lyon Sud, Lyon 1 University, Lyon, France

Received 2 October 2008 ,Accepted 12 March 2009.

References 

  1. Schröder FH, Carter HB, Wolters T, et al. Early detection of prostate cancer in 2007 (Part 1: PSA and PSA kinetics). Eur Urol. 2008;53:468–477
  2. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44:8–15
  3. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59:5975–5979
  4. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006;15:R17–R29
  5. Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology. 2003;62:34–43
  6. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695–2698
  7. Popa I, Fradet Y, Beaudry G, et al. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol. 2007;20:1121–1127
  8. Bialkowska-Hobrzanska H, Driman DK, Fletcher R, et al. Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue. Can J Urol. 2006;13:2967–2974
  9. Landers KA, Burger MJ, Tebay MA, et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer. 2005;114:950–956
  10. Balcerczak E, Mirowski M, Sasor A, et al. Expression of p65, DD3 and c-erbB2 genes in prostate cancer. Neoplasma. 2003;50:97–101
  11. van Bokhoven A, Varella-Garcia M, Korch C, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate. 2003;57:205–225
  12. van Gils MP, Cornel EB, Hessels D, et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate. 2007;67:881–887
  13. Tinzl M, Marberger M, Horvath S, et al. DD3PCA3 RNA analysis in urine—a new perspective for detecting prostate cancer. Eur Urol. 2004;46:182–186
  14. Fradet Y, Saad F, Aprikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 2004;64:311–315
  15. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006;52:1089–1095
  16. van Gils MP, Hessels D, van Hooij O, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 2007;13:939–943
  17. Haese A, de la Taille A, van Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008;54:1081–1088
  18. Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007;69:532–535
  19. Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008;179:1804–1809
  20. Shappell SB, Fulmer J, Arquello D, et al. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology. 2009;73:363–368
  21. Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179:1587–1592
  22. Sokoll LJ, Ellis W, Lange P, et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clinica Chim Acta. 2008;389:1–6
  23. Magklara A, Scolaris A, Stephan C, et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology. 2000;56:527–532
  24. Bostwick DG, Gould VE, Qian J, et al. Prostate cancer detected by uPM3: radical prostatectomy findings. Mod Pathol. 2006;19:630–633
  25. van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate. 2008;68:1215–1222
  26. Whitman EJ, Groskopf J, Ali A, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol. 2008;180:1975–1978
  27. Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res. 2007;13:5103–5108
  28. Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008;68:645–649

PII: S0090-4295(09)00512-3

doi: 10.1016/j.urology.2009.03.046

Urology
Volume 75, Issue 2 , Pages 447-453 , February 2010

Article Tools

* Image Usage & Resolution